MedPath

Cyclarity Therapeutics, Inc.

Cyclarity Therapeutics, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2019-11-01
Employees
1
Market Cap
-
Website
http://www.cyclaritytx.com

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Early Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Early Phase 1
1 (100.0%)

Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Patients

Early Phase 1
Recruiting
Conditions
Atherosclerotic Cardiovascular Disease
Acute Coronary Syndromes
Interventions
Other: Placebo
First Posted Date
2025-02-06
Last Posted Date
2025-05-02
Lead Sponsor
Cyclarity Therapeutics, Inc.
Target Recruit Count
84
Registration Number
NCT06813339
Locations
🇦🇺

CMAX Clinical Research, Adelaide, South Australia, Australia

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.